• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem Diabetes Care stock down on Q4 misses

February 23, 2023 By Sean Whooley

Tandem Diabetes CareTandem Diabetes Care (Nasdaq:TNDM) shares are down today on fourth-quarter results that came up shy of the consensus forecast.

Shares of TNDM were down more than 6% to $37.28 apiece by midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up more than 8%.

Yesterday evening, the San Diego-based automated insulin delivery technology maker posted losses of $15.85 million. That amounts to losses per share of 25¢ on sales of $220.5 million for the three months ended Dec. 31, 2022.

Tandem recorded a bottom-line slide into the red from profits of $10.8 million this time last year. However, sales grew by 5% from the same three-month period in 2021.

Wall Street analysts expected sales totaling $221.8 million and losses per share of 6¢. Tandem came up shy of those figures on both counts.

Positives for Tandem ahead of projected 2023 growth

Still, the company cites a handful of steps forward over the course of 2022. That includes acquisitions of infusion set maker Capillary Biomedical and patch pump developer AMF Medical. The Capillary Biomedical acquisition brought on a $31 million impact to Tandem’s GAAP financial results for the year.

Tandem also increased its worldwide installed base by 29% to approximately 420,000 customers this past year. Renewal pump shipments in the U.S. increased by approximately 60% compared to 2021. The company said it exited 2022 with a record growth rate in renewal pump shipments totaling 75% in the fourth quarter.

“In 2022, we continued to expand the worldwide insulin pump market, bringing the benefits of our t:slim X2 technology to more people living with diabetes,” said John Sheridan, Tandem president and CEO. “In the year ahead, we are focused on driving growth by promoting our best-in-class Control-IQ technology, with future acceleration to come from delivering multiple new product innovations.”

Tandem set its 2023 guidance for non-GAAP revenues between $885 million and $900 million. That represents an annual sales growth of 10% to 12% compared to 2022.

This story originally ran on Feb. 22, 2022. Updated Feb. 23 with the next-day stock price. 

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS